Company: CERO
Filing Date: 2025-08-11
Form Type: S-3
Source: 0001213900-25-073849
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-11
Form: S-3
Chunk 3
---
 not receive any proceeds from the
resale of Common Stock by the Selling Stockholders pursuant to this prospectus. We expect to require substantial additional capital to
support our operations and execute our business plan, including the development and manufacturing of our product candidates, and the payment
of deferred expenses incurred in connection with the Business Combination. We will be required to raise capital in part through the issuance
of our equity or equity-based securities, the issuance of which may have an adverse effect on the price of our Common Stock. However,
we may be unable to raise capital or additional financing when needed on acceptable terms, or at all. See the sections entitled “Information
Related to Offered Securities” and “Risk Factors-Risks Related to Ownership of Our Securities.”

We will pay the expenses, other than any underwriting
discounts and commissions, associated with the resale of securities pursuant to this prospectus. The Selling Stockholders will bear all
commissions and discounts, if any, attributable to their sales of the shares of Common Stock. We are registering the Selling Stockholders’
securities for resale pursuant to the Selling Stockholders’ registration rights under the Registration Rights Agreement, dated April
22, 2025, by and among CERo and certain investors (the “Fourth PIPE Registration Rights Agreement”). Our registration of the
securities covered by this prospectus does not mean that the Selling Stockholders will offer or sell, as applicable, any of the securities.
The Selling Stockholders may offer and sell the securities covered by this prospectus in a number of different ways and at varying prices.
We provide more information about how the Selling Stockholders may sell the shares in the section entitled “Plan of Distribution.”

This prospectus provides you with a general description
of such securities and the general manner in which the Selling Stockholders may offer or sell the securities. More specific terms of any
securities that the Selling Stockholders may offer or sell may be provided in a prospectus supplement that describes, among other things,
the specific amounts and prices of the securities being offered and the terms of the offering. The prospectus supplement may also add,
update or change information contained in this prospectus.

You should read this prospectus and any prospectus
supplement or amendment carefully before you invest in our securities.

Our Common Stock and public warrants to purchase Common Stock (the
“Public Warrants”) are listed on Nasdaq Capital Market under the symbol “CERO” and “CEROW,” respectively.
On August 7, 202